{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T20:40:48Z","timestamp":1777927248578,"version":"3.51.4"},"reference-count":26,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[2018,10,31]],"date-time":"2018-10-31T00:00:00Z","timestamp":1540944000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Int J STD AIDS"],"published-print":{"date-parts":[[2019,2]]},"abstract":"<jats:p>No single-tablet antiretroviral (ARV) regimens (STRs) are approved for patients with human immunodeficiency virus (HIV) and end-stage renal disease (ESRD) on hemodialysis (HD). Based on known pharmacokinetic (PK) properties, abacavir (ABC)\/lamivudine (3TC)\/dolutegravir (DTG) STR may represent a promising option. This case series presents the safety and efficacy of ABC\/3TC\/DTG STR in patients with HIV and ESRD on HD. Patients were included if they were HIV-positive, maintained on intermittent HD for ESRD, switched to an ARV regimen containing ABC\/3TC\/DTG, and had at least one set of virologic data before and after the switch. Average age (\u00b1standard deviation) was 59 (\u00b18) years. The majority of patients were cis-gender male and non-Hispanic Black. Only one demonstrated clinically significant resistance at baseline. All were on multiple-tablet regimens prior to the switch. Five patients (83%) achieved undetectable HIV-RNA after the switch while only four patients (46%) were undetectable immediately prior. No decline in immune function was noted. ABC\/3TC\/DTG STR was well tolerated. Only one patient self-reported an adverse event (nausea), which resolved without drug discontinuation. Based on these data, it appears that ABC\/3TC\/DTG may be a safe and effective ARV-STR option for patients with HIV and ESRD on HD. A larger trial including a PK analysis is needed to confirm these findings.<\/jats:p>","DOI":"10.1177\/0956462418800865","type":"journal-article","created":{"date-parts":[[2018,10,31]],"date-time":"2018-10-31T23:26:40Z","timestamp":1541028400000},"page":"181-187","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":18,"title":["Abacavir\/lamivudine\/dolutegravir single tablet regimen in patients with human immunodeficiency virus and end-stage renal disease on hemodialysis"],"prefix":"10.1177","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1182-7997","authenticated-orcid":false,"given":"Sarah M","family":"Michienzi","sequence":"first","affiliation":[{"name":"Department of Pharmacy Practice, Section of Infectious Diseases Pharmacotherapy, College of Pharmacy, University of Illinois at Chicago, Chicago, IL, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher A","family":"Schriever","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, College of Pharmacy, University of Illinois at Chicago, Rockford, IL, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melissa E","family":"Badowski","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, Section of Infectious Diseases Pharmacotherapy, College of Pharmacy, University of Illinois at Chicago, Chicago, IL, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2018,10,31]]},"reference":[{"key":"bibr1-0956462418800865","unstructured":"Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents living with HIV. Department of Health and Human Services, http:\/\/aidsinfo.nih.gov\/contentfiles\/lvguidelines\/AdultandAdolescentGL.pdf (accessed 1 October 2017)."},{"key":"bibr2-0956462418800865","unstructured":"GlaxoSmithKline. Epivir (lamivudine) (package insert). Research Triangle Park, NC: GlaxoSmithKline, 2016."},{"key":"bibr3-0956462418800865","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.8.2387-2392.2002"},{"key":"bibr4-0956462418800865","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.1998.00044.x"},{"key":"bibr5-0956462418800865","doi-asserted-by":"publisher","DOI":"10.1159\/000045870"},{"key":"bibr6-0956462418800865","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.40.6.1514"},{"key":"bibr7-0956462418800865","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-199212000-00008"},{"key":"bibr8-0956462418800865","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12407"},{"key":"bibr9-0956462418800865","doi-asserted-by":"publisher","DOI":"10.1592\/phco.19.11.932.31568"},{"key":"bibr10-0956462418800865","doi-asserted-by":"publisher","DOI":"10.1159\/000046045"},{"key":"bibr11-0956462418800865","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200847060-00001"},{"key":"bibr12-0956462418800865","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.43.12.2855"},{"key":"bibr13-0956462418800865","unstructured":"GlaxoSmithKline. Ziagen (abacavir) (package insert). Research Triangle Park, NC: GlaxoSmithKline, 2017."},{"key":"bibr14-0956462418800865","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00292-13"},{"key":"bibr15-0956462418800865","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.03131-15"},{"key":"bibr16-0956462418800865","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000001086"},{"key":"bibr17-0956462418800865","unstructured":"GlaxoSmithKline. Tivicay (dolutegravir) (package insert). Research Triangle Park, NC: GlaxoSmithKline, 2017."},{"key":"bibr18-0956462418800865","unstructured":"HIV drug interactions. University of Liverpool, www.hiv-druginteractions.org (accessed 1 October 2017)."},{"key":"bibr19-0956462418800865","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciu701"},{"key":"bibr20-0956462418800865","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfv207"},{"key":"bibr21-0956462418800865","doi-asserted-by":"publisher","DOI":"10.1097\/MNH.0b013e328349c261"},{"key":"bibr22-0956462418800865","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0144119"},{"key":"bibr23-0956462418800865","doi-asserted-by":"publisher","DOI":"10.1086\/313849"},{"key":"bibr24-0956462418800865","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000001677"},{"key":"bibr25-0956462418800865","doi-asserted-by":"publisher","DOI":"10.1089\/apc.2017.0081"},{"key":"bibr26-0956462418800865","doi-asserted-by":"publisher","DOI":"10.1086\/374601"}],"container-title":["International Journal of STD &amp; AIDS"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/0956462418800865","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/0956462418800865","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/0956462418800865","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T22:38:48Z","timestamp":1777675128000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/0956462418800865"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,31]]},"references-count":26,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["10.1177\/0956462418800865"],"URL":"https:\/\/doi.org\/10.1177\/0956462418800865","relation":{},"ISSN":["0956-4624","1758-1052"],"issn-type":[{"value":"0956-4624","type":"print"},{"value":"1758-1052","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,31]]}}}